Theseus Pharmaceuticals (THRX) – Press Releases
-
Theseus Pharmaceuticals Announces Closing of Tender Offer
-
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
-
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
-
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
-
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
-
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
-
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
-
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
-
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference
-
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
-
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
-
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
-
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
-
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
-
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
-
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Third Quarter 2022 Financial Results
-
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
-
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
-
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer
-
Theseus Pharmaceuticals to Participate at Upcoming September Investor Conferences
-
Theseus Pharmaceuticals Announces Business and Pipeline Highlights and Reports Second Quarter 2022 Financial Results
-
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
-
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
-
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
-
Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual
-
Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference
-
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Theseus Pharmaceuticals to Present Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual
-
Theseus Pharmaceuticals to Participate Virtually in SVB Leerink Global Healthcare Conference
-
Theseus Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for THE-630 for the Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
-
Theseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
-
Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies
-
Theseus Pharmaceuticals Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
-
Theseus Pharmaceuticals to Participate Virtually in Jefferies London Healthcare Conference
-
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering
-
Jeff Jonker Joins Ambys Medicines as President and CEO
-
Theravance, Inc. Announces Name Change to Innoviva, Inc.
-
Theravance, Inc. Announces Preliminary Results of Tender Offer
-
Theravance to Present at Two Upcoming Investor Conferences in November
-
Theravance, Inc. Announces Commencement of Self-Tender Offer for up to $75,000,000 of Its Common Stock
-
Theravance Reports Third Quarter 2015 Financial Results
-
Theravance to Report Third Quarter 2015 Financial Results on October 28, 2015
-
GSK Presents Post-Hoc Analysis of Anoro(R) Ellipta(R) Data Assessing Markers of COPD Deterioration Compared to Tiotropium or Placebo Using a Novel Composite Endpoint
-
Regulatory Update: GSK and Theravance Announce Intention to File Relvar(R) Ellipta(R) for COPD in Japan
-
GSK and Theravance Announce Results From the SUMMIT COPD CV Survival Study
-
Theravance to Present at Two Upcoming Investor Conferences in September
-
GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma
Back to THRX Stock Lookup
